2 results
Approved WMOCompleted
To gain insight in the cognitive basis of the positive effect of apomorphine on visual hallucinations in Parkinson's disease (PD)
Approved WMORecruiting
To evaluate the safety and tolerability of treatment with atogepant 60 mg once daily when administered over 156 weeks for the prevention of migraine in participants with Chronic Migraine (CM) or Episodic Migraine (EM).